ContraFect Stock Price - CFRX

0.10 (1.83%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
ContraFect Corporation CFRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.06 1.11% 5.45 4.45 5.52 4.73 5.39 00:00:00
Bid Price Ask Price Spread Spread % News
5.45 5.92 0.47 7.94% - 1
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
9,693 1,944,121 $ 5.00 $ 9,714,170 201,895 0.2693 - 13.25
Last Trade Time Type Quantity Stock Price Currency
19:59:30 formt 300 $ 5.55 USD

ContraFect Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 83.56M 15.33M 13.87M $ - $ - -1.58 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 9.50%

more financials information »

ContraFect News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CFRX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week5.406.104.455.68134,3450.050.93%
1 Month6.937.45874.456.19132,468-1.48-21.36%
3 Months8.3210.504.456.57142,374-2.87-34.5%
6 Months0.379913.250.2771.59950,7765.071,334.59%
1 Year0.44913.250.26931.24676,3465.001,113.81%
3 Years1.25513.250.26931.10460,7914.20334.26%
5 Years5.0613.250.26931.26298,3860.397.71%

ContraFect Description

ContraFect Corp is a cinical-stage biotechnology company which focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases including those caused by drug-resistant pathogens, particularly treated in hospital settings. The company has developed advanced lysin product candidate, CF-301 for the treatment of Staph aureus bacteremia, including endocarditis. It also emphasizes on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The company operates through a single segment being the Development of therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.